dolutegravir + boceprevir

This is a **combination therapy** of *dolutegravir* (an HIV-1 integrase strand transfer inhibitor) and *boceprevir* (an HCV NS3/4A protease inhibitor). **Dolutegravir** inhibits HIV replication by blocking the integration of viral DNA into the host genome, targeting the integrase enzyme. **Boceprevir** targets the hepatitis C virus by inhibiting the NS3/4A serine protease, preventing viral polyprotein processing and replication. Coadministration of dolutegravir and boceprevir is used in patients **coinfected with HIV and HCV**, and studies indicate no clinically significant pharmacokinetic interactions or need for dose adjustment when administered together. The combination offers a treatment strategy for controlling both viruses in coinfected patients[1][2].

Other names

dolutegravir + boceprevir